TABLE 1.
Rates of antibacterial resistance among P. aeruginosa isolates from hospitals and ICUs
| Antibiotic | % of strains exhibiting resistancea |
|||||||
|---|---|---|---|---|---|---|---|---|
| Hospital study, 2006 (n = 606) (211) | Hospital study, 2005 (n = 589) (212) | Hospital study, 2002 (n = 9,896) (54) | ICU study, 2002 (n = 951) (178) | ICU study, 2000-2002 (n ≥ 7,500) (95) | Hospital study, 2001 (n ≥ 2,157) (99) | ICU study, 2001 (n ≥ 543) (99) | Hospital study, 2000 (n = 882) (100) | |
| β-Lactams | ||||||||
| Cefepime | 6 | 5 | 9 | 25 | 12 | 8 | 10 | 9 |
| Ceftazidime | 13 | 10 | 13 | 19 | 17 | 9 | 9 | 13 |
| Piperacillin-tazobactam | 11 | 9 | 11 | 10 | 14 | 8 | 8 | 13 |
| Aztreonam | 12 | 32 | ||||||
| Imipenem | 11 | 7 | 16 | 23 | 22 | 12 | 16 | 16 |
| Meropenem | 6 | 7 | 18 | 11 | 16 | 10 | ||
| Fluoroquinolones | ||||||||
| Ciprofloxacin | 21 | 22 | 35 | 32 | 33 | 26 | 25 | 25 |
| Levofloxacin | 22 | 22 | 34 | 32 | 27 | 25 | 27 | |
| Aminoglycosides | ||||||||
| Amikacin | 5 | 10 | 4 | 3 | ||||
| Tobramycin | 8 | 10 | 12 | 16 | ||||
| Gentamicin | 12 | 12 | 16 | 22 | 15 | 15 | 14 | |
a
Based upon CLSI interpretive breakpoints.